Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new model help botswana shield infants from RSV?

NCT ID NCT07756528

Knowledge-focused Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This study aims to create a health economic model that estimates the costs and health benefits of different RSV prevention strategies for infants in Botswana. Researchers will gather input from policymakers, healthcare providers, funders, and other stakeholders through interviews, workshops, and surveys. The model is intended to help decision-makers understand whether and how to introduce RSV prevention tools, such as monoclonal antibodies. No RSV product will be tested in infants, and no medical treatment will be provided.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help Botswana's health leaders decide whether and how to introduce RSV prevention for infants, potentially reducing severe illness and hospitalizations.
What could go wrong
This is a modeling and engagement study, not a clinical test of an RSV product. The model's usefulness depends on data quality and stakeholder input, and it may not fully predict real-world outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

We will establish a 20-member stakeholder advisory board representing policymakers (n=5), funders (n=3), healthcare providers (n=5), researchers (n=2), and leaders representing patient groups (n=5).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Expertise or Role: 1. Policymakers: Currently employed in or recently retired from a government health agency, Ministry of Health, or other institution with responsibility for health policy, immunization, or maternal/child health. 2. Funders: Employed by or affiliated with an organization that funds health services, immunization programs, or health research in Botswana or the region. 3. Healthcare providers: Licensed clinicians (e.g., pediatricians, nurses, midwives) with direct experience delivering maternal or child health services in Botswana. 4. Researchers: Active or recent experience in health economics, public health, or RSV-related research, with relevance to LMICs. 5. Patient representatives: Affiliated with or leading a civil society or patient advocacy organization focused on child health, immunization, or health equity in Botswana. 2. Geographic Relevance: Based in Botswana or with demonstrated experience working within Botswana's health system or policy landscape. 3. Language: Comfortable speaking and reading English or Setswana.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RSV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RSV

Contacts and locations

Locations

  • Botswana Harvard Health Partnership

    Gaborone, Gaborone, Botswana

More trials for these conditions

Other studies related to the condition(s) this trial covers.